Accelerating Regenerative Medicine
Empowering Cell & Gene Therapy with AI
with AI
CytoHub - Crafting Cells for Cures. Founded by distinguished drug developers, we are your development partner in cell therapy development, facilitating the seamless transition from discovery to commercialization. Harnessing the power of Artificial Intelligence and Machine Learning, we strive to transform healthcare's future, pioneering breakthrough cell therapies and regenerative solutions. Our mission: to revolutionize cell therapy production and delivery, making it faster, affordable, and universally accessible. Embrace the future with CytoHub, your gateway to the revolution in cell therapy.
Bridging the Gaps
Next-Generation Partner Offering Tools, Products and Services to Global Market
Delivering cutting-edge cell therapies and regenerative solutions.
Recent News
Aitor Aguirre, Ph.D., Joins CytoHub as Scientific Advisor, Boosting AI-Driven Therapeutic Innovations
CytoHub proudly welcomes Aitor Aguirre, Ph.D., a distinguished Associate Professor from Michigan State University, as our new Scientific Advisor. His expertise will propel our AI-driven therapeutic innovations to new heights.
Frank Teoh Joins as VP, Global Head of BioEngineAI Platform, Bringing 20+ Years of Engineering Leadership
CytoHub welcomes Frank Teoh as Vice President, Global Head of BioEngineAI Platform, bringing over two decades of engineering leadership and innovation. With achievements that include $100M+ in business impact and 9 patents, Frank’s expertise will steer CytoHub to new frontiers in AI-driven therapeutics.
Enthusiastic Welcome to David H. Crean, Ph.D., Our New Advisory Board Member at CytoHub!
David is a renowned Venture Investor, Investment Banker, and Mentor, known for assisting healthcare and life sciences entrepreneurs. His appointment significantly bolsters our Advisory Board’s strength, promising valuable insights and strategic direction for CytoHub’s growth.
Warm Welcome to Oscar J. Abilez, MD, PhD, CytoHub's Principal Consultant, CM Organoids!
We are delighted to announce the recent addition of Oscar J. Abilez, MD, PhD, as our Principal Consultant, CM Organoids. This appointment expands and strengthens our capabilities.
Our collaborative approach is aimed at speeding up your research and facilitating the successful progression of your project. We achieve this by helping you meet your milestones and delivering accurate and timely assay results at each stage of your drug discovery process while ensuring compliance.
Process Development
Development of scalable cell therapy processes for clinical trials and commercialization
Drug Discovery
Using pluripotent stem cells as tools for efficient drug discovery and development
Bioreactor Scale-up
Optimizing bioreactor systems to meet the demands of scaling up cell therapy production
Analytical Development
Assays to assess the quality, safety, functionality, and efficacy of cell therapy products
Tech Transfer
Facilitate the efficient transfer of cell therapy manufacturing processes to CMOs
Cell Banking
Expansion of starting materials and cryopreservation in quantities for GMP or RUO purposes
Technology Evaluation
Assessment of the cell therapy technology for scientific strength, novelty, and clinical potential
Gene Editing
Modification of cell lines for proliferation, immune evasion, or other traits of interest
Research & Development
Services to accelerate the discovery, characterization, optimization, and clinical translation of cell therapies